China cell therapy developer Neowise raises $29m
Chinese cell therapy company Neowise has raised an extended Series A round of CNY200m (USD 29m) from a group including Oriza Seed Fund Management and Marathon Venture Partners.
Shenzhen-listed urban mine resource exploitation company GEM Group, TongGao Capital, Zhongxin Capital, and Suzhou-based Leader Venture Capital also participated. Existing investor TF Capital re-upped....
More on Greater China
Latest News
HKEX relaxes rules for IPOs by pre-profit tech companies
The Hong Kong Stock Exchange (HKEX) has loosened its listing requirements to allow pre-profit technology companies to go public with market capitalisations as low as HKD 6bn (USD 764m).
Asia GPs must get smarter on target selection, costs - Bain & Co
Careful target selection – based on geography and sector – and increased emphasis on cost controls during ownership will be critical factors for Asian private equity investors as the industry braces for a downturn, according to Bain & Company.
Longreach buys Japan healthcare SaaS player
North Asia buyout specialist The Longreach Group has invested an undisclosed sum in Wellness Communications Corporation (WCC), a Japanese healthcare software-as-a-service (SaaS) provider.
Asia-Europe investor AGIC supports Danish electronics buyout
AGIC Capital, a specialist in Europe-China cross-border deals, has backed the acquisition of PR Electronics, a Danish manufacturer of signal processing equipment with an existing base in China.